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Curative resection is the treatment of choice for potentially curable gastric cancer. Two major Western studies in the 1990s failed to
show a benefit from D2 dissection. They showed extremely high postoperative mortality after D2 dissection, and were criticised for
the potential inadequacy of the pretrial training in the new technique of D2 dissection, prior to the phase III studies being initiated.
The inclusion of pancreatectomy and splenectomy in D2 dissection was associated with increased morbidity and mortality. Following
these results, we started a phase II trial to evaluate the safety and efficacy of pancreas-preserving D2 dissection. The results of this trial
regarding the safety of pancreas preserving D2 dissection were published in 1998. In this paper, we present the survival results of this
phase II trial to confirm the rationale of carrying out a phase III study comparing D1 vs D2 dissection for curable gastric cancer.
Italian patients with histologically proven gastric adenocarcinoma were registered in the Italian Gastric Cancer Study Group
Multicenter trial. The study was carried out based on the General Rules of the Japanese Research Society for Gastric Cancer. A strict
quality control system was achieved by a supervising surgeon of the reference centre who had stayed at the National Cancer Center
Hospital, Tokyo, to learn the standard D2 gastrectomy and the postoperative management. The standard procedure entailed
removal of the first and second tier lymph nodes. During total gastrectomy, the pancreas was preserved according to the Maruyama
technique. Complete follow-up was available to death or 5 years in 100% of patients and the median follow-up time was 4.38 years.
Out of 297 consecutive patients registered, 191 patients were enrolled in the study between May 1994 and December 1996. The
overall morbidity rate was 20.9%. The postoperative in-hospital mortality was 3.1%. The overall 5-year survival rate among all eligible
patients was 55%. Survival was strictly related to stage, depth of wall invasion, lymph node involvement and type of gastrectomy
(distal vs total).
Our results suggest a survival benefit for pancreas-preserving D2 dissection in Italian patients with gastric cancer if performed in
experienced centres. A phase III trial among exclusively experienced centres is urgently needed.
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Gastric cancer, which is the commonest cancer in Japan, remains a
major cause of death also in Western countries. In Italy, it
represents the third most frequent cause of death from cancer in
both male and female patients (Decarli et al, 1998). Data from
Italian Cancer Registries show a 27% 5-year survival rate (Rosso
et al, 2001). This is consistent with other survival rates reported in
Western countries. On the contrary, large retrospective Japanese
series have shown significantly higher 5-year survival rates after
radical gastrectomy. This impressive difference is largely related to
earlier diagnosis, but it is possible that the more extensive lymph
node dissection performed in Japan, where the stomach is usually
removed along with the first and second tier nodal stations (D2
gastrectomy) (Sasako et al, 1997), also contributes.
Favourable patient survival after D2 gastrectomy has also been
reported by some other non-Japanese retrospective nonrando-
mised trials (Pacelli et al, 1993; Siewert et al, 1993).
Nevertheless, the two large prospective randomised trials
recently performed in the West (the MRC and the Dutch
randomised surgical trials) failed to demonstrate a survival benefit
for D2 gastrectomy as compared to D1 resection (Bonenkamp et al,
1999; Cuschieri et al, 1999). Furthermore, these trials showed a
significant increase in post-operative morbidity and mortality after
extended dissection.
These unfavourable results have been attributed mainly to the en
bloc removal of the spleen and the tail of the pancreas for middle
and upper third tumours in the D2 arms of both trials.
Furthermore, the lack of experience in this technique of dissection
and in postoperative care by each surgeon participating in these
trials has been claimed as one of the reasons for the results
(Bonenkamp et al, 1995; Cuschieri et al, 1996). Both studies were
carried out without pretrial training and without preliminary
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studies to confirm the safety of the procedure locally, and were
concluded before many surgeons would have reached the plateau
of the learning curve.
The Italian Gastric Cancer Study Group (IGCSG) was set up in
1994 to confirm the safety and efficacy in survival of D2 resection
with pancreas preservation, and a strict quality control system was
implemented in a prospective one-arm phase II study. In 1998, we
showed comparable postoperative morbidity and mortality rates
with those reported after the standard resection, and documented
that the D2 resection with preservation of the pancreas could be
offered as a safe radical treatment of gastric cancer for Western
patients in experienced centres (Degiuli et al, 1998).
We now report the survival data of the patients of the same trial.
PATIENTS AND METHODS
Eligibility and assessment of curability
Patients eligible for participation in this study were to have
histologically proven and preoperatively potentially curable
adenocarcinoma of the stomach. Patients who required emergency
procedures, who harboured a coexisting cancer, who were 480
years old or who had a comorbid cardiorespiratory dysfunction
that would preclude more extensive dissection were excluded.
After preoperative staging to exclude clinical evidence of distant
metastasis, all patients were registered and underwent staging
laparotomy. Eligible cases were those without any evidence of
peritoneal and/or liver metastasis, involvement of the oesophagus,
cardias or duodenum, and biopsy-proven metastasis in para-aortic
and/or retropancreatic nodes.
Treatment
The surgical protocol was based on the general rules of the
Japanese Research Society for Gastric Cancer (JRSGC, 1981a, b).
The D2 dissection entailed removal of the first and second tier
nodes along with the lymph nodes of the left side of the
hepatoduodenal ligament. During total gastrectomy, the spleen
was removed while the tail of the pancreas was preserved
according to the technique described by Maruyama et al (1995),
unless it was suspected to be invaded by the tumour. In the case of
a clinical T1 tumour, splenectomy was not carried out.
Distal gastrectomy was performed in cases of early gastric
cancer (EGC) or well demarcated advanced gastric cancer (AGC),
such as Borrman type 1 or 2, with a tumour-free margin of at least
2 cm, or in case of infiltrative AGC, type 3 or 4, with a tumour-free
margin of at least 5 cm to the proximal resection line. A total
gastrectomy was performed in all other cases.
For all enrolled patients, chemotherapy was not given until
recurrence was diagnosed.
Pathological classification
As compared with our previous papers, tumours were restaged
according to the fifth edition of UICC TNM Classification of
Malignant Tumours and the Japanese Classification of Gastric
Carcinoma, 2nd English edition (UICC, 1997; JGCA, 1998).
Quality control
A surgeon from the reference centre (MD) stayed at the National
Cancer Center Hospital, Tokyo, to learn the D2 dissection from a
specialist Japanese surgeon (MS). He was given didactic videos,
papers and explanatory booklets edited by Japanese authors. MD
became the supervisor of the trial.
The IGCSG was set up in April 1994 and nine institutions
participated. Each centre had two surgeons attending all the
operations.
Before starting the trial, several meetings were organised among
participating centres to explain the terminology, to debate the
proper indications and demonstrate the surgical technique. At
least one of the two surgeons of each participating institution
observed the first 10 procedures in this trial, which were
performed at the reference centre. Afterwards, MD attended the
first three operations performed at each institution.
Registration
The study was organised and directed from a central office at the
reference centre (Department of Oncology, Division of Surgery,
Turin, Italy). Data on enrolment, surgical procedures, histopatho-
logic findings, postoperative course and patient follow-up evalua-
tion were collected by the surgeon at each institution and posted to
the data centre at the central office. Patients were followed up at
regular intervals: every 3 months during the first 2 years and every
6 months thereafter. In addition, an enquiry on vital status and
cause of death was collected for all patients at the municipal roster
office. The final follow-up date was 31 December 2002. Complete
follow-up was available in 100% of patients; the median follow-up
time for those alive at the end of the study was 7.4 years.
Statistical methods
Sample size calculations were performed assuming to achieve a 5-
year overall survival of 50%, intermediate between Western and
Japanese series. The required number for enrolment was then set
to about 200 patients, based on the desired level of power precision
in estimating this parameter (95% confidence interval: 42.9–
57.1%, power 80%). Confidence intervals are based on exact
binomial probabilities. Overall survival was computed by the
Kaplan–Meier method using the BMDP statistical package for all
eligible subjects and for subpopulations grouped on the basis of
selected variables. Both deaths due to the disease and deaths
without evidence of recurrence were counted as events in the
analysis of survival. The gastric cancer-specific survival curve was
also calculated, with deaths due to other causes being censored.
RESULTS
In total, 297 patients with histologically proven adenocarcinoma of
the stomach were registered from the nine institutions over 212
years (May 1994 – December 1996). Of these, 106 patients were
found ineligible for the study mostly because more advanced
disease was identified at laparotomy, as outlined in the protocol. In
all, 191 patients fulfilled the criteria of eligibility and were entered
into the study. Table 1 briefly summarises the characteristics of the
eligible patients (median age: years), the procedures performed,
the pathologic stage of the disease and the early outcome.
No patients were lost to follow-up. The median follow-up time of
all patients alive at the end of the study was 7.4 years (range 6 –8.7
years). All patients were followed up till death or for at least 6
years. Of the 191 resected patients, 96 (50.3%) died. Six out of these
96 patients died with early postoperative complications (3.1%).
During the follow-up, 26 patients (13.6%) died without recurrence
of gastric cancer. Death with recurrence of gastric cancer occurred
in 70 patients (36.7%).
Decrease of postoperative in-hospital mortality
Postoperative in-hospital mortality may have decreased during the
study period. It was 5.26% in 1994 (38 procedures performed),
2.11% in 1995 (95 procedures) and 1.75% in 1996 (57 procedures).
Although suggestive of a decreasing trend, due to small numbers
percentages are not significantly different from each other
(X2¼ 0.36 (df 2), P¼ 0.55; X2 slope¼ 0.94 (df 1), P¼ 0.33).
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Overall survival
For calculating the incidence of deaths due to the disease (n¼ 70),
the cause of death according to clinical records was used. In those
few records where the cause was missing, the cause of death listed
in the Piemonte Cancer Registry (from the municipal roster office)
was used.
The overall 5-year survival rate among all eligible patients was
55.0% (95% confidence interval 47.9, 62.1) (Figure 1). The gastric
cancer specific survival rate was 65% after 5 years and 62.5% after
6 years (Figure 1).
Survival by TNM stages
The 5-year survival rate was significantly dependent upon the stage
of the disease (Po0.001). It was 95, 87.5, 57.5, 42.5, 22.5 and 2.5%
in patients with TNM stage IA, IB, II, IIIA, IIIB and IV, respectively
(Figure 2). To allow comparison of these results with other reports,
the results using the previous TNM classification are also shown in
Table 2.
Survival by depth of invasion
Survival of patients was significantly influenced by depth of
invasion (Po0.001). The 5-year survival rate was 90, 52.5, 25 and
12.5 for patients with T1, T2, T3 and T4, respectively (Figure 3).
Survival by nodal involvement
We analysed patient survival according to the two nodal staging
systems: the 1997 TNM and the 1998 JGCA classification.
The. 5-year survival rates of pN0, pN1, pN2 and pN3 by 1997
TNM were 85, 52.5, 32.5 and 2.5%, respectively. Those by the JGCA
classification were 47.5%, 35 % and 0% for pN1, pN2 and pN3,
respectively (Figure 4).
Survival by type of gastrectomy
Patients who underwent distal gastrectomy showed a higher 5-year
survival rate (70%) as compared with those who received total
resection (40%) (Po0.001).
Table 1 Patient characteristics
No. of patients (%)
(191¼ 100%)
No. of patients
(%) (191¼ 100%)
Sex M/F 114 (59.6)/77 (41.4) IIIB 25 (13.1)
Age o50 years 31 (16.2) IV 23 (12.1)
Age 50–69 years 103 (53.9) Pathological
stage
Age 70+ years 57 (29.8) T1 68 (35.6)
Location of tumour T2 58 (30.3)
Distal third (A,AM) 116 (60.8) T3 58 (30.3)
Middle third
(M,MC,CM)
52 (27.2) T4 7 (3.8)
Upper third (C,CM)l 13 (6.8) Nodal status
More than two-thirds
of stomach
6 (3.1) N0 78 (35.4)
Stump 4 (2.1) N1 41 (21.5)
Japanese stage
grouping
N2 56 (29.3)
IA 53 (27.7 ) N3 (location
no 12)
16 (8.4)
IB 22 (11.5) Type of
gastrectomy
II 31 (16.2) Distal 124 (64.9)
IIIA 37 (19.4) Total 67 (35.1)
1.00
0.80
0.60
0.40
0.20
0.0
0 1 2 3 4 5 6 7 8 9 10
Figure 1 Overall 5-year survival among all eligible. patients (J) and
among patients with deaths related to cancer only (C) (95% confidence
interval 47.9, 62.1).
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Figure 2 Survival after resection according to 1997 TNM stage (A is IA;
B is IB; C is II; D is IIIA; E is IIIB; F is IV).
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DISCUSSION
The role of the extended lymph node dissection in improving long-
term survival after gastrectomy for gastric cancer is still not proven
by RCTs. Moreover, the Dutch and British trials have shown
increased morbidity and mortality figures after D2 gastrectomy
(Bonenkamp et al, 1995; Cuschieri et al, 1996). Potential reasons
for this unfavourable outcome include the lack of surgical
skilfulness/training and poor quality control, and the routine
removal of the spleen and tail of the pancreas in total gastrectomy
(Cuschieri et al, 1996).
In our previous paper, we showed that it is possible to achieve
low morbidity and mortality after extended lymph node dissection,
if the operation is performed in specialised centres with a strict
quality control system, and without removing the pancreas during
total gastrectomy unless it is suspected to be involved by the
tumour (Degiuli et al, 1998).
The present study has also shown good survival data. The
overall 5-year survival rate was 55%. Moreover, the disease-specific
5-year survival was 65%. Our results are almost equivalent to those
reported by Sasako after 2541 extended gastrectomies performed at
the National Cancer Center Hospital, Tokyo, during the period
‘1982–1991’ (66%) (Sasako et al, 1997, pp 223– 248). Not only the
overall survival rate but also the stage-specific survival rates after
D2 dissection were much better in this study than those of the D2
arm of the Dutch and MRC trials (Table 2).
Table 2 Survival among all eligible patients and according to old TNM stage in the most recent series
Author No of patients Type of gastrectomy (No. of patients) 5 years survival (%) IA IB II IIIA IIIB IV
Wanebo et al (1993) 9057 D0–1 26 59 44 29 15 9 3
Siewert et al (1993) 1182a D1 (379) 86 72 26 25 27 28
D2 (803) 85 68 55 38 17 16
Pacelli et al (1993)b 238b D2 65 96 73 63 40 33 0
Cuschieri et al (1999) 400 D1 (200) 35 69 22 11 Not included
D2 (200) 33 58 31 11
Bonenkamp et al (1999)b 711b D1 (380) 34 81 60 38 11 13 0
D2 (331) 81 61 42 28 13 28
D1 (380) 33
D2 (331)
Sasako et al (1997) 2541 D2–4 66 92 90 76 59 36 7
IGCSG et al (2004) 191 D2 55 92.5 87.5 60 40 20 2.5
aOnly Ro resection. bOnly curative resection.
1.00
0.80
0.60
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0.0
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Figure 3 Survival by depth of invasion (pT) (A is T1; B is T2; C is T3; D is
T4).
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Figure 4 Survival by JGCA nodal involvement (A is N0;B is N1; C is N2;
D is N3).
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The discrepancy between our data and data from other Western
series could be explained by differences in the patient population
or by differences in surgical technique.
Regarding the patient populations, the eligibility criteria from
the two large prospective randomised series are totally comparable
to those adopted in our trial.
With respect to the clinical and pathological stages, no major
differences appear in the reported series apart from a clear
prevalence of early gastric cancer in the Japanese series. The
prevalence of early tumours (stage I disease) is close to 50% in the
Japanese series, while it is 35.6% in our population, 36% in the
MRC series, 26% in the Dutch trial and 19.6% in an American
patient care study (16). Siewert gives the figures for IA and IB
stages, which are, respectively, 13.8 and 13.4% (3). In the present
series, the number of patients with TNM stage less than III is
substantial (106 patients, 55.4%) and might be partly responsible
for our good survival data.
To avoid the confounding effect of stage migration,
we should compare the results of series reporting D2
dissection with each other. Our results are similar to those
previously reported by Pacelli et al. (1993) in their retrospective
trial and by Siewert et al (1993) in their prospective nonrando-
mised trial.
The main criticism that has been directed towards the
recent prospective randomised European trials has been
the lack of experience of the surgeons participating in the
study. The contrast in postoperative mortality between the Dutch
or British trials and our own study clearly demonstrated the
danger of carrying out this procedure, let alone an RCT, without
sufficient pretrial training. Clearly a one-arm study, equivalent to
the phase II study in medical treatment, is an appropriate
preliminary to a phase III trial of complex and potentially
hazardous surgery. MS, who was supervisor of both the Dutch
and the Italian study, believes that the Dutch study was flawed by
early randomisation of patients, and the inclusion of many small-
volume hospitals. It is suggested that a new surgical technique
requiring not only surgical skills but also good experience in
postoperative care should only be tested in an RCT after
completion of sufficient training to carry it out safely. In fact,
the reported perioperative mortalities in these two major RCTs on
D2 dissection were over 10%. Pancreaticoduodenectomy for
pancreatic cancer or radical oesophagectomy for oesophageal
cancer are more surgically aggressive procedures than D2
gastrectomy and are recommended to be performed exclusively
in specialised centres. They do not carry a risk of hospital
mortality of over 10% in such centres (Altorki and Skinner, 1997;
Gordon et al, 1998; Bottger and Junginger, 1999; Lerut et al, 1999;
Tsiotos et al, 1999; Gouma et al, 2000; Karl et al, 2000).
Postoperative mortality of over 10% is no longer acceptable in
any kind of cancer surgery.
Our own experience correlates well with the data given
by Parikh et al (1996) about the duration of the learning
curve for D2 dissection, which should be more than 15 procedures.
Each participating centre treated 15 to more than 25 patients
(seven procedures per year on an average) (Table 3), and
in every centre each patient was always treated by the same
two surgeons. Therefore, each centre and each surgeon should
have reached an optimal experience level, acquiring sufficient
technical skills regarding intra- and postoperative care during this
trial. Our results support the argument for training the surgeons
prior to the initiation of a clinical trial although, at a practical level,
a study target of 700–1000 patients would be very difficult to
conduct, and it might take more than 10 years to recruit all the
patients.
We observed an overall postoperative in-hospital mortality of
3.1%: this rate has been decreasing from 5.2% in 1994, to 2.11% in
1995 and finally to 1.7% in 1996. While not statistically significant,
this trend supports the concept of a learning curve.
As already indicated, subset analysis of the Dutch
and MRC trials documented that the higher morbidity in the D2
arm is mostly due to pancreas and spleen removal (Cuschieri et al,
1996). Hence, pancreas preservation was adopted as standard
procedure in D2 dissection in the present trial. Therefore, the
pancreas was removed only when it was suspected to be involved
by the tumour (T4). Furthermore, during total gastrectomy,
splenectomy was not carried out in patients with clinical T1
tumour (Table 4).
After confirming the low mortality and acceptable morbidity of
pancreas-preserving D2 dissection, we started a phase III trail,
comparing D1 vs D2 in 1998. The survival results shown in this
paper suggest the benefits of D2 dissection, although a statistically
significant survival advantage needs to be confirmed through this
new randomised phase III trial. The aim of this phase III trial is to
document an increase of survival in the D2 arm with acceptable
increase of morbidity and without increase of mortality.
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Table 3 Relative experience of participating centres in Italian, British and
Dutch trials.
IGCSG DGCGa MRCb
No. of centres 9 80 322
No. of surgeons 9 pairs 11/85c 32
Duration of enrolment (years) 2.5 4 7
No of patients 191 331 200
Average no. of procedures/hospital/year 7 1.5 1
aDutch Gastric Cancer Group trial. bMedical Research Council, British Trial.
cSupervising/local surgeons.
Table 4 Spleen and pancreas removal during total gastrectomies in
Italian, British and Dutch trials
IGCSG no. (%) DGCGa no. (%) MRCb no. (%)
Total gastrectomies 67 (100) 126 (100) 108 (100)
Splenectomies 49 (73.1) 124 (98.4) 131 (121.2)c
Pancreatectomies 10 (14.9) 98 (77.7) 113 (104.6)d
aMedical Research Council, British trial. bDutch Gastric Cancer Group trial. cA total of
25 splenectomies performed during a distal gastrectomy. dFive pancreatectomies
performed during a distal gastrectomy.
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